This would be in line with macrophage-dependent ADCP as reported in the initial clinical trial of combination treatment with murine CD24 and CD21 mAbs of B-cell lymphoma patients [47,48]. The gene discussed is CD24; the disease is B-cell non-Hodgkin lymphoma.